Following ‘CRISPR Babies’ Scandal, Senators Call for International Gene Editing Guidelines
By Andrew Joseph,
STAT+
| 07. 15. 2019
A bipartisan trio of senators has introduced a resolution underscoring their opposition to the experiments last year in China that led to the birth of the world’s first genome-edited babies.
A bipartisan trio of senators on Monday introduced a resolution underscoring their opposition to the experiments last year in China that led to the birth of the world’s first genome-edited babies.
The resolution from Sens. Dianne Feinstein (D-Calif.), Marco Rubio (R-Fla.), and Jack Reed (D-R.I.) also reiterated support for international groups working to produce guidelines for the clinical use of germline editing — meaning changes to the DNA in sperm, eggs, or early embryos that would be passed down to future generations.
If passed, the resolution would not change U.S. law; editing embryos with the purpose of creating children is already illegal in the United States. But the action by the senators stands out, since some members of Congress have recently expressed some openness to lifting the ban on editing embryos used to start pregnancies. Scientists in other countries have also announced plans to continue pursuing such experiments, and some scientific and patient advocacy groups have emphasized how germline editing, once the technology improves, could stave off cases of genetic disease.
“Gene editing is a powerful technology that...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...